Communications Biology (Feb 2022)
Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture
- Xuanting Wang,
- Carolina Q. Sacramento,
- Steffen Jockusch,
- Otávio Augusto Chaves,
- Chuanjuan Tao,
- Natalia Fintelman-Rodrigues,
- Minchen Chien,
- Jairo R. Temerozo,
- Xiaoxu Li,
- Shiv Kumar,
- Wei Xie,
- Dinshaw J. Patel,
- Cindy Meyer,
- Aitor Garzia,
- Thomas Tuschl,
- Patrícia T. Bozza,
- James J. Russo,
- Thiago Moreno L. Souza,
- Jingyue Ju
Affiliations
- Xuanting Wang
- Center for Genome Technology and Biomolecular Engineering, Columbia University
- Carolina Q. Sacramento
- Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz)
- Steffen Jockusch
- Center for Genome Technology and Biomolecular Engineering, Columbia University
- Otávio Augusto Chaves
- Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz)
- Chuanjuan Tao
- Center for Genome Technology and Biomolecular Engineering, Columbia University
- Natalia Fintelman-Rodrigues
- Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz)
- Minchen Chien
- Center for Genome Technology and Biomolecular Engineering, Columbia University
- Jairo R. Temerozo
- Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz)
- Xiaoxu Li
- Center for Genome Technology and Biomolecular Engineering, Columbia University
- Shiv Kumar
- Center for Genome Technology and Biomolecular Engineering, Columbia University
- Wei Xie
- Laboratory of Structural Biology, Memorial Sloan-Kettering Cancer Center
- Dinshaw J. Patel
- Laboratory of Structural Biology, Memorial Sloan-Kettering Cancer Center
- Cindy Meyer
- Laboratory of RNA Molecular Biology, Rockefeller University
- Aitor Garzia
- Laboratory of RNA Molecular Biology, Rockefeller University
- Thomas Tuschl
- Laboratory of RNA Molecular Biology, Rockefeller University
- Patrícia T. Bozza
- Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz)
- James J. Russo
- Center for Genome Technology and Biomolecular Engineering, Columbia University
- Thiago Moreno L. Souza
- Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz)
- Jingyue Ju
- Center for Genome Technology and Biomolecular Engineering, Columbia University
- DOI
- https://doi.org/10.1038/s42003-022-03101-9
- Journal volume & issue
-
Vol. 5,
no. 1
pp. 1 – 14
Abstract
In this paper, the hepatitis C virus inhibitors Pibrentasvir and Ombitasvir are found to inhibit the SARS-CoV-2 exonuclease and are shown to have therapeutic potential when combined with SARS-CoV-2 polymerase inhibitors in viral cell cultures.
